• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai, June 1

Wockhardt Ltd has received regulatory approval from the United States Food and Drug Administration (US FDA) for marketing Clarithromycin antibiotic tablets in the US market. Clarithromycin is the generic version of Abbott's Biaxin tablets. Wockhardt's US subsidiary, Wockhardt USA Inc is expected to launch the broad-spectrum macrolide antibiotic within the next two weeks, a note from the company said. The current market for this product in the US is estimated to be $113 million.

More Stories on : Standards & Benchmarks | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Bosch to double common rail systems capacity

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line